Methods and compositions for the assessment of drug response

Abstract

The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided

We claim: 
     
         1 . A method comprising:
 a) analyzing a sample from a subject with a SNP detection assay to determine that said subject is homozygous for the −806C/T polymorphism in the CYP2C19 gene (CYP2C19*17), thereby generating homozygous CYP2C19*17 genetic analysis result data;   b) receiving said homozygous CYP2C19*17 genetic analysis result data into a system, wherein said system comprises:
 i) a computer processor for receiving, processing, and communicating data, 
 ii) a storage component for storing said homozygous CYP2C19*17 genetic analysis result data, and 
 iii) a computer program, embedded within said computer processor, which is configured to process said homozygous CYP2C19*17 genetic analysis result data in order to generate outcome data; 
   c) processing said homozygous CYP2C19*17 genetic analysis result data with said computer program to generate said outcome data;   d) communicating said outcome data from said computer program; and   e) administering to said subject, based on said outcome data, decreased loading and/or maintenance dosages of said clopidogrel compared to CYP2C19 wild-type dosage levels.   
     
     
         2 . The method of  claim 1 , further comprising the step of analyzing said sample with a SNP detection assay for the presence or absence of the 636 G>A polymorphism in said CYP2C19 gene (CYP2C19*3 polymorphism). 
     
     
         3 . The method of  claim 2 , further comprising the step of analyzing said sample with a SNP detection assay for the presence or absence of the 19154G/A polymorphism in said CYP2C19 gene (CYP2C19*2 polymorphism).